Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomised, Double Blind, Placebo Controlled and Open Label Phase Multicentre Study to Investigate the Efficacy and Safety of BTX-A-HAC NG in the Treatment of Moderate to Severe Glabellar Lines, and Assess the Long Term Efficacy and Safety of BTX-A-HAC NG Following Repeated Treatments in This Indication

NCT02493946 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT02493946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02493946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomised, Double Blind, Placebo Controlled and Open Label Phase Multicentre Study to Investigate the Efficacy and Safety of BTX-A-HAC NG in the Treatment of Moderate to Severe Glabellar Lines, and Assess the Long Term Efficacy and Safety of BTX-A-HAC NG Following Repeated Treatments in This Indication
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2015
Completion date
December 31, 2016
Enrollment
600 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines